Neuropsychobiology最新文献

{"title":"Effect of acute administration of different ketamine doses on anxiety and metabolic activity of the amygdala in rats.","authors":"Manuel Alejandro Guevara, Sebastián Marcelo García Menéndez, Iker Barrutieta-Arberas, Esteban Alejandro Romanowicz, Adriana Inés Landa de Gargiulo, José Vicente Lafuente, Pascual Ángel Gargiulo","doi":"10.1159/000547982","DOIUrl":"https://doi.org/10.1159/000547982","url":null,"abstract":"<p><strong>Introduction: </strong>Anxiety has been described in the initial stages of schizophrenia, and affective flattening in the chronic illness. The etiology remains unknown. Ketamine, a noncompetitive N-Methyl-D-amino-aspartate acid (NMDA) receptor antagonist, is used in rats as a translational model of schizophrenia. A glutamate deficit within Nucleus Accumbens Septi (NAS) afferent projections has been proposed to be involved in schizophrenia. The amygdala is related to memory, fear and anxiety, and is closely linked to the NAS. Here, we studied anxiety in male rats using the elevated plus-maze (EPM) after receiving acute administration of different subanesthetic doses of ketamine. The metabolic state of the amygdala was measured after ketamine treatment. The main aim of the present study is to compare the effect of different doses as emulating progressive stages of schizophrenia.</p><p><strong>Methods: </strong>Classical anxiety parameters were observed during elevated plus maze (EPM) experiments in rats with the low doses of ketamine. After this, amygdalas were randomly extracted and submitted to a test of redox cellular metabolic activity with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT).</p><p><strong>Results: </strong>Low doses (1.25 and 2.5 mg/kg) significantly decreased time spent in the open arm, time per entry and open arm entries, and increased time in the closed arms and grooming. These doses also decreased metabolic activity.</p><p><strong>Conclusion: </strong>We conclude that the administration of subanesthetic doses of ketamine exert an acute anxiogenic effect in the plus maze test at the lower doses, accompanied by a decrease in amygdala metabolic activity, suggesting metabolic exhaustion. The higher doses reversed the anxiety parameters, suggesting an explanation of the opposite symptoms in schizophrenia progression.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-14"},"PeriodicalIF":3.1,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Sex in Clinical Characteristics and Pharmacological Treatment of Bipolar Disorder.","authors":"Erik Putz, Elena M D Schönthaler, Nina Dalkner, Frederike T Fellendorf, Adelina Tmava-Berisha, Susanne A Bengesser, Melanie Lenger, Robert Queissner, Alexander Maget, Alfred Häussl, Tatjana Maria Stross, Eva Z Reininghaus, Alexander Finner, Julia Ilic","doi":"10.1159/000548338","DOIUrl":"https://doi.org/10.1159/000548338","url":null,"abstract":"<p><strong>Introduction: </strong>There has been an increasing focus on sex differences in bipolar disorder in recent years, yet much remains to be understood about their impact on clinical characteristics and treatment approaches. The aim of this study is to identify sex differences that could alter diagnosis and treatment strategies, potentially improving patient compliance and outcomes.</p><p><strong>Methods: </strong>This retrospective study analysed data from interviews with 340 participants (171 men, 169 women; ages ranging from 18 to 82 years) from the BIPFAT/BIPLONG study at the specialised outpatient centre for bipolar disorder at the Medical University of Graz, Austria. We examined sex differences in clinical characteristics and drug therapy primarily using logistic and linear regression models, with chi-square tests and Mann-Whitney U tests applied as supplementary analyses for subgroup comparisons.</p><p><strong>Results: </strong>Our findings revealed that the age of onset for bipolar disorder was earlier in women (B = -3.05, 95% CI = [-5.08, -1.02], p = .003), with women reporting their first affective symptoms at an average age of 22.7 (SD = 9.9) compared to 26.4 (SD = 12.1) in men. Comorbid obsessive-compulsive disorder was significantly more prevalent in women (OR = 2.24, 95% CI = [2.12, 41.33], p = .003). In comparison, men were shown to experience manic episodes per year more frequently (B = -.32, 95% CI = [-.59, -.05], p = .019). Differences in treatment emerged only within specific age subgroups rather than the overall study sample.</p><p><strong>Conclusions: </strong>Overall, we found fewer differences than expected, which suggests that factors other than sex play a greater role in the course of bipolar disorder. Our analysis indicates that more women are suffering from OCD as comorbidity than men, a topic that has not yet been extensively researched. While previous studies mostly show that men have an earlier onset of symptoms, we found the opposite in our sample. Another notable difference in illness course was that men experienced more manic episodes per year. Further research in this area is needed to verify our findings, ideally focusing specifically on OCD in bipolar men and women, as sex differences in this comorbidity remain underexplored.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-21"},"PeriodicalIF":3.1,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring Blood Glutamate as a Diagnostic Biomarker for Major Depressive Episodes in a context of Major Depressive Disorder.","authors":"Khalil El Asmar, Tala El Ghoul, Romain Colle, Hugo Bottemanne, Rida Assaf, Séverine Martin, Séverine Trabado, Bruno Fève, Céline Verstuyft, Laurent Becquemont, Emmanuelle Corruble","doi":"10.1159/000548339","DOIUrl":"https://doi.org/10.1159/000548339","url":null,"abstract":"<p><strong>Introduction: </strong>Major depressive disorder (MDD) represents a critical public health issue, impacting millions globally and significantly contributing to disability-adjusted life years (DALYs). Major Depressive Episode (MDE) is a feature of MDD characterized by severe depressive symptoms. The role of glutamate, a primary excitatory neurotransmitter, in MDD has been extensively studied and several drugs improving MDE/MDD impact the glutamate cascade; however, findings regarding blood glutamate levels in patients with a current MDE in a context of MDD remain inconsistent. This study aims to compare blood glutamate levels between MDE/MDD patients and matched controls.</p><p><strong>Methods: </strong>We conducted a matched case-control study utilizing 185 cases from the METADAP multicentric prospective study (NCT00526383), which was conducted from November 2009 to March 2013, and 185 controls from the VARIETE cohort (NCT01831648), conducted between January 2011 and February 2012. Blood glutamate levels were assessed from plasma samples collected between 8:00 and 10:00 a.m. after an overnight fast. The same method was used for patients and controls.</p><p><strong>Results: </strong>No significant blood glutamate level differences were observed between the 185 cases and matched controls of this study [conditional logistic regression: OR = 0.99, 95% CI (0.98-1.01), p = 0.74].</p><p><strong>Conclusion: </strong>Further research is warranted to investigate brain glutamate levels and whether glutamate levels of MDE/MDD patients could predict response to conventional antidepressant drugs and anti-glutamatergic drugs such as ketamine.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-11"},"PeriodicalIF":3.1,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145006397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic Effects and Safety of Mirtazapine for Insomnia in Major Depressive Disorder: Findings from a 6-Week Open-Label Pre- and Post-Intervention Study.","authors":"Mohammad Tariqul Alam, Ahsan Aziz Sarkar, Muhammad Zillur Rahman Khan, Helal Uddin Ahmed, Abdullah Al Mamun, Mahbub Hasan, Rubina Hossain, Taiyeb Ibna Zahangir, Nadia Afroz, Afroza Rahman Lopa, Nayem Akhter Abbassi, Syed Reazur Rahman, Mahfuza Yasmin, Tayabur Rahman, Akm Khaleequzzaman, Dipesh Sonawane, Kalpesh Joshi, Sameer Eknath Rao, Suyog Mehta","doi":"10.1159/000547983","DOIUrl":"https://doi.org/10.1159/000547983","url":null,"abstract":"<p><strong>Introduction: </strong>Insomnia is one of the most common symptoms of depression, estimated to occur in approximately 75% of adult patients with depression, and it may persist even after remission from depressive episodes. Our objectives were to evaluate the efficacy of mirtazapine in reducing insomnia and depression symptom severity, assess side effects, and compare quality of life before and after intervention in major depressive disorder (MDD) patients with insomnia.</p><p><strong>Methods: </strong>This was a single-center, prospective, open-label, quasi-experimental pre-post intervention trial of six weeks. The Hamilton Depression Rating Scale (HDRS), Insomnia Severity Index (ISI), Antidepressant Side-Effect Checklist (ASEC), and World Health Organization Quality of Life (WHOQOL-BREF) tools were used during the assessment.</p><p><strong>Results: </strong>Out of the 135 recruited patients, 109 (80.7%) completed the trial. On day 14, with a mean dose of 18.9 mg/day, 24.8% of patients experienced remission for insomnia, while 7.3% showed remission for depression. By day 42, with a mean dose of 18.7 mg/day, these figures increased to 62.4% for insomnia and 41.3% for depression. The reduction in the ISI score (mean±SD) from baseline to day 14 and day 42 was 8.74±6.16 and 13.55±5.32, respectively. Similarly, the reduction in the HDRS score from baseline on day 14 and 42 was 10.30±6.89 and 17.78±6.26, respectively. The most commonly reported adverse effects (>10%) included increased appetite, drowsiness, weight gain, dry mouth, headache, and constipation. Regarding QoL, the differences were significant for all four domains with the highest improvement observed in the physical (mean difference 25.67±13.95) and psychological domains (mean difference 26.35±16.42) of QoL.</p><p><strong>Conclusion: </strong>Mirtazapine treatment was associated with significant improvements in depression, insomnia, and all QoL parameters, with increased appetite and weight gain being the most common adverse effects. Further randomized controlled comparator studies will be beneficial for healthcare providers to improve the clinical care of MDD patients with insomnia.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-17"},"PeriodicalIF":3.1,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On Anxiolytic and Antidepressant Effects of Curcumin in Sepsis-Induced Post-Intensive Care Syndrome: Antioxidant and Anti-Inflammatory Effects.","authors":"Mei Guo, Yiqi Zhang, Huili Yang, Qingyan Liu","doi":"10.1159/000547791","DOIUrl":"10.1159/000547791","url":null,"abstract":"<p><strong>Introduction: </strong>Post-intensive care syndrome (PICS) encompasses a range of physical, cognitive, and mental impairments frequently observed in individuals who have undergone intensive care unit treatment. This study aimed to investigate the potential of curcumin (CuC) in mitigating anxiety- and depressive-like behaviors associated with sepsis-induced PICS in mice.</p><p><strong>Methods: </strong>To establish a PICS model, male C57/B6 mice were subjected to sublethal cecal slurry (CS) injection to induce sepsis. The mice were orally administered CuC at doses of 10, 25, and 50 mg/kg, respectively, or fluoxetine at a dose of 10 mg/kg for a duration of 3 weeks. Anxiety and depression were assessed using the open field test, tail suspension test, and forced swimming test. At the end of the study, the mice were sacrificed, and their hippocampi (HC) were isolated for molecular analyses.</p><p><strong>Results: </strong>The behavioral tests revealed anxiety- and depressive-like behaviors in the CS-exposed animals. CuC at 25 and 50 mg/kg, but not 10 mg/kg, mitigated anxiety- and depressive-like behaviors in sepsis-induced PICS mice. Additionally, upregulation of NF-κB, NLRP3, Caspase 1, and ASC genes and protein levels of IL1β, IL6, IL18, and TNFα were observed in the HC of CS-exposed animals. Furthermore, the hippocampal concentrations of oxidative stress biomarkers, including glutathione peroxidase, superoxide dismutase, and malondialdehyde, were found to be dysregulated.</p><p><strong>Conclusion: </strong>The administration of CuC demonstrated the ability to reverse the detrimental effects of CS. The modulation of immune response by CuC underscores its potential as an antidepressant and protective agent against sepsis-induced PICS, suggesting its viability as a potential therapeutic tool for sepsis treatment.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-17"},"PeriodicalIF":3.1,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of Organic Cation Transporter 3 (SLC22A3) Genetic Polymorphisms on Antidepressant Maintenance Doses in Japanese Patients with Depression.","authors":"Kazuyuki Inoue, Kakeru Nagaoka, Natsuko Ando, Yasuhiro Hakamata, Kunihiko Itoh","doi":"10.1159/000548094","DOIUrl":"10.1159/000548094","url":null,"abstract":"<p><strong>Introduction: </strong>Interindividual variations in antidepressant dosages required to achieve and maintain a therapeutic response are common. To mitigate the risk of recurrence, it is recommended that patients maintain treatment at a dose that effectively alleviates their acute depressive symptoms for at least 6 months. This study investigated the relationship between the antidepressant doses used for maintenance therapy and genetic polymorphisms that affect serotonin transporter activity.</p><p><strong>Methods: </strong>Eighty-four Japanese patients with depression were enrolled in the study. For each patient, the doses of antidepressant and anxiolytic/hypnotic medications were quantified as equivalents of imipramine and diazepam, respectively, based on the most recent prescription. Patients were divided into high- and low-dose antidepressant treatment groups, using the median dose as the between-group cutoff. We examined the influence of genetic polymorphisms on inclusion in the high- and low-dose groups.</p><p><strong>Results: </strong>Multivariate logistic regression analysis revealed that the presence of the G allele in the SLC22A3 rs2292334 polymorphism was associated with an increased antidepressant maintenance dose. The odds ratio for an increased presence in the G allele of the SLC22A3 rs2292334 polymorphism was 8.867 (95% confidence interval, 1.869-42.069).</p><p><strong>Conclusion: </strong>These findings have potential use in informing future dosing strategies in depression therapy.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"1-8"},"PeriodicalIF":3.1,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional Annotation of Bipolar Disorder 2 Risk Location Implicates Novel Susceptibility Genes.","authors":"Güneş Şayan Can, Ebru Bakır, Yavuz Oktay","doi":"10.1159/000543504","DOIUrl":"10.1159/000543504","url":null,"abstract":"<p><strong>Introduction: </strong>Bipolar 2 disorder (BD2) is an independent disease with specific familial aggregation, significant functional impairment, specific treatment challenges, and several distinctive clinical features. However, unlike bipolar 1 disorder, studies investigating causal and functional genes are lacking. This study aimed to identify and prioritize causal genetic variants and genes for BD2 by analysing brain-specific gene expression markers, improve the understanding of its genetic underpinnings, and support advancements in diagnosis, treatment, and prognosis.</p><p><strong>Method: </strong>We used FUMA, a genome-wide association study (GWAS) annotation tool, to pinpoint potential causal variants and genes from the largest BD2 GWAS data. Candidate causal variants most likely affecting brain gene expression were prioritized using the following criteria: (1) variants identified as eSNPs in any brain region within any brain expression quantitative trait loci (eQTL) dataset; (2) variants annotated in the Regulome database with a score <5, indicating likely functional localization; (3) the most common 15-core chromatin state across all cell types in the Roadmap Epigenomics data being ≤7, reflecting an open chromatin state; (4) localization in genomic regions with evidence of 3D chromatin interactions, as such interactions mediate genetic effects on gene expression.</p><p><strong>Results: </strong>We identified AGRN, ORMDL3, SLC25A39, RUNDC3A, NOS2, C1orf159, RP11-5407.18, RP11-465B22.3, RP11-5407.17 as candidate causal genes. These genes are associated with important pathways such as synapse formation, mitochondrial and oxidative metabolism, intracellular transport, neurotransmission, and lipid metabolism-related pathways.</p><p><strong>Conclusion: </strong>This study provides a guide for further experimental validation of functional variants, BD2-associated genes, and novel drug targets.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"65-73"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety Profile of Lithium: A Disproportionality Analysis Using the FDA Adverse Event Reporting System.","authors":"Hao Zhu, Jack Guo, Hannah Lui, Patrick Ip","doi":"10.1159/000546602","DOIUrl":"10.1159/000546602","url":null,"abstract":"<p><p><p>Introduction: Although lithium has long been considered the gold standard for mood stabilization in the treatment of bipolar disorder, growing concerns about its adverse events have significantly undermined its once-trusted status. This study aims to conduct a pharmacovigilance analysis of lithium to provide a more comprehensive understanding of its safety profile.</p><p><strong>Methods: </strong>Four disproportionality analysis methods, including reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and empirical Bayes geometric mean (EBGM), were employed to detect potential signals between lithium and various adverse events.</p><p><strong>Results: </strong>Analysis of 6,909 adverse event reports from the FDA Adverse Event Reporting System (FAERS) showed that lithium-related adverse events occur in the endocrine, renal or urinary, nervous, and psychiatric systems. Well-known adverse events, such as hypothyroidism, nephrogenic diabetes insipidus, and ataxia, were found. In addition, several previously overlooked adverse events, such as renal oncocytoma, benign parathyroid tumor, and Adams-Stokes syndrome, were identified.</p><p><strong>Conclusion: </strong>By analyzing real-world data, this study provides a comprehensive evaluation of lithium's safety profile, offering critical evidence for its clinical risk. However, given the inherent limitations of FAERS, such as underreporting of minor symptoms, the findings should be interpreted cautiously. </p>.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"175-183"},"PeriodicalIF":3.1,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12215163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144199738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between miR-27a rs895819 Polymorphism and Antidepressant Treatment Response in Patients with Depression.","authors":"Yanle Bai, Junjuan Zhu, Chunhu Zhang, Kuancai Deng, Yingzhi Xu","doi":"10.1159/000546405","DOIUrl":"10.1159/000546405","url":null,"abstract":"<p><strong>Introduction: </strong>Depression is a prevalent mental health disorder. miR-27a regulates neuronal development. This study aimed to investigate the association between the miR-27a rs895819 polymorphism and antidepressant treatment response in patients with depression.</p><p><strong>Methods: </strong>The expression level of miR-27a was detected by reverse transcription-polymerase chain reaction. The genotype of rs895819 was performed by PCR-restriction fragment length polymorphism. The condition of patients was evaluated by a 17-item Hamilton Depression Rating Scale (HAMD-17) (reduction rate = [HAMD-17 baseline - HAMD-17 8 weeks]/HAMD-17 baseline × 100%). Effective response was defined as a reduction rate of ≥50%. Remission was defined as HAMD-17 ≤17. The association between SNP and depression risk was calculated by the χ2 test. Logistic regression analysis was performed to evaluate the effects of SNP on antidepressant treatment response.</p><p><strong>Results: </strong>There were 173 patients with depression and 186 healthy controls. rs895819 was negatively correlated with depression under CC versus TT (p = 0.044, OR = 0.412, 95% CI = 0.170-0.996), CC + TC versus TT (OR = 0.607, 95% CI = 0.397-0.927), and C versus T (OR = 0.633, 95% CI = 0.448-0.896) models. miR-27a expression was significantly decreased in individuals with TC/CC genotypes than TT genotypes. rs895819 (TC/CC) was positively correlated with the effective response (p = 0.005, OR = 2.551, 95% CI = 1.322-4.920).</p><p><strong>Conclusion: </strong>rs895819 TC/CC genotypes were significantly correlated with depression and associated with increased effective response.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"167-174"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Forced Running Attenuates Depression-Like Behavior and Hippocampal Inflammatory Response in Mice Induced by Chronic Unpredictable Mild Stress.","authors":"Qian Zhong, Mengqi Duan","doi":"10.1159/000544843","DOIUrl":"10.1159/000544843","url":null,"abstract":"<p><strong>Introduction: </strong>As a late proinflammatory factor, the role of high-mobility group box 1 (HMGB-1) in nervous system inflammation has been widely studied. The inflammatory response mediated by HMGB-1 plays an important role in the pathophysiological mechanism of depression. This study aimed to investigate the antidepressant effects of forced running on chronic unpredictable mild stress (CUMS) mice by examining the impact on hippocampal HMGB-1.</p><p><strong>Methods: </strong>The experiment included a comparison with the traditional broad-spectrum antidepressant fluoxetine to evaluate the potential benefits of forced exercise or combined therapy. Mice were divided into different groups - control, forced running + fluoxetine (FR + FLU), CUMS, CUMS + forced running (CUMS + FR), CUMS + fluoxetine (CUMS + FLU), and CUMS + forced running + fluoxetine combined therapy (CUMS + FR + FLU). The study used the tail suspension test (TST), forced swimming test (FST), and sucrose preference test (SPT) to assess depression-like behavior. Following the experiment, the levels of hippocampal HMGB-1 and associated proteins and cytokines were measured.</p><p><strong>Results: </strong>The results revealed that 4 weeks of forced running significantly attenuated depression-like behavior and reduced the expression of HMGB-1-associated inflammatory proteins and cytokines in CUMS mice. Conversely, fluoxetine showed limited effectiveness in reversing depression-like behavior but demonstrated a reduction in the expression of hippocampal HMGB-1-associated inflammatory proteins and cytokines. The combined therapy also exhibited significant antidepressant effects and reduced levels of HMGB-1-associated inflammatory proteins and cytokines, with a faster response compared to forced running alone.</p><p><strong>Conclusion: </strong>Forced running may offer potential benefits in modulating the anti-inflammatory response associated with HMGB-1, providing insights into the potential therapeutic role of physical exercise in managing depression.</p>","PeriodicalId":19239,"journal":{"name":"Neuropsychobiology","volume":" ","pages":"133-145"},"PeriodicalIF":2.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143605831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"心理学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}